Aducanumab was the first therapy to demonstrate that removing beta-amyloid, one of the hallmarks of Alzheimer's disease, from the brain reduces cognitive and functional decline in people living with …

Aducanumab, sold under the brand name Aduhelm, is an anti-amyloid drug designed to treat Alzheimer's disease. [1][2] It is a monoclonal antibody [2][1] that targets aggregated forms (plaque) …

Oct 27, 2025 · What is aducanumab? Aducanumab is used to treat adults with Alzheimer's disease. Aducanumab may also be used for purposes not listed in this medication guide.

Aducanumab is a monoclonal antibody selective for amyloid β (Aβ) aggregates. In June 2021, aducanumab became the first drug underlying the pathophysiology of Alzheimer’s disease (AD) …

The FDA has approved the medicine aducanumab, for the treatment of Alzheimer’s disease. This is the first new Alzheimer’s drug approved in 18 years and the first therapy that can slow progression of …

2 days ago · Aducanumab, sold under the brand name Aduhelm, is not an effective treatment for Alzheimer’s disease by most meaningful clinical standards, and it carries significant safety risks. The …

Aug 19, 2025 · Given as an intravenous (into-the-vein) infusion once every four weeks, the treatment’s active ingredient, aducanumab, targets aggregated beta-amyloid, helping to reduce the buildup of …

Aducanumab (marketed as Aduhelm) Information Aduhelm is an amyloid beta-directed antibody indicated to treat Alzheimer’s disease.

Oct 30, 2025 · With a strong focus on difficult-to-treat diseases, our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational …

Jun 30, 2024 · Aducanumab (Aduhelm) is a discontinued drug for Alzheimer’s disease with mild cognitive impairment. It’s a monoclonal antibody that works by removing amyloid proteins – …